Furthermore, the panel used in this study did not include the RB gene, which was thought to predict the efficacy of CDK4/6 inhibitors [56], or the ESR1 or PIK3CA genes, which were frequently observed in breast cancer and were considered involved in endocrine therapy resistance [19,20,21,22,57]. The gene discussed is PIK3CA; the disease is breast carcinoma.